x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

The Cancer Letter

The Cancer Letter

The Cancer Letter, an independent weekly news publication, has been the leading source for information on the issues that shape oncology since 1973. With a dedicated audience of oncology’s leaders, The Cancer Letter stays on top of breaking news and advances in oncology, providing authoritative, award-winning coverage of the development of cancer therapies, drug regulation, legislation, cancer research funding, health care finance, and public health. This weekly podcast features interviews,

health & fitness medicine

All Episodes

00:37:02

Could mRNA vaccines hold the key to building an...

The Cancer Letter ·

2026/01/14

“I believe in the concept of a universal cancer vaccine,” said Elias Sayour, a pediatric oncologist at the University of Florida. “I think if this fails in a prospective phase III trial, I still believe we can engineer a vaccine that works prospectively.”The cover story of last week’s issue of The Cancer Letter was about the potential of COVID-19 mRNA vaccines to improve response to checkpoint inhibitor therapies in patients with lung cancer and melanoma. The finding was published by Sayour and his

en

00:27:28

Nancy Goodman: “Sen. Sanders says he cares about kids...

The Cancer Letter ·

2026/01/07

On Dec. 19, the Mikaela Naylon Give Kids a Chance Act was blocked in the Senate by Sen. Bernie Sanders (I-VT) after receiving unanimous approval from the U.S. House of Representatives Dec. 1. On this episode of The Cancer Letter Podcast, Nancy Goodman, founder and executive director of Kids v. Cancer, joins Jacquelyn Cobb, associate editor with The Cancer Letter, and Claire Marie Porter, reporter. Goodman walks Jacquelyn and Claire through the emotional highs and lows that have characterized the

en

01:04:20

Otis Brawley looks back on a year of great science...

The Cancer Letter ·

2025/12/31

In a year that brought us new KRAS-inhibiting drugs, deepened our understanding of HER2 in breast cancer, and highlighted new potential for mRNA vaccines, the cancer field was also rocked by uncertainty of the future of research funding, equity in cancer delivery, and the integrity of review at FDA. In a lively conversation with The Cancer Letter’s Paul Goldberg, Brawley, who is the Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University and co-editor of the Cancer

en

00:39:55

2025 in review: In a mess, there is movement—and...

The Cancer Letter ·

2025/12/24

A year like 2025 has demanded a lot from all of us, between the Trump administration’s flooding of the zone, the impact of DOGE and MAHA initiatives on the National Cancer Program, and the personal toll of living amidst uncertainty. In many ways, 2025 was a test. Did the field of oncology pass? Did The Cancer Letter? Reflecting on a year of cancer news coverage and our readers’ most-read stories, Paul Goldberg, editor and publisher of The Cancer Letter, and Jacquelyn Cobb, associate editor, talk

en

00:45:36

The Directors: Joann Sweasy and Robert Winn reflect...

The Cancer Letter ·

2025/12/19

As trust in scientific and regulatory institutions frays and the meaning of “gold standard science” is increasingly contested, cancer research faces a credibility test of its own. “Cancer research is apolitical,” Joann Sweasy, director of the Fred & Pamela Buffett Cancer Center, and president of the Association of American Cancer Institutes, said. “Everyone is impacted by cancer. I don't know any family that's not impacted by cancer.”Sweasy said since the Trump administration took over

en

00:21:47

Testing for asbestos in talc-based cosmetics seems...

The Cancer Letter ·

2025/12/17

Last month, FDA withdrew a proposed rule for standardized asbestos testing in talc-based cosmetics. The proposed rule, introduced in Nov. 2024 and withdrawn Nov. 2025, was mandated by the Modernization of Cosmetics Regulation Act of 2022 or MoCRA.Following an open comment period, FDA decided to withdraw the rule—citing significant public opposition and unintended consequences.“When you read the headline: ‘They're withdrawing a proposed rule that would regulate asbestos,’ it's hard to see how

en

00:27:29

Richard Pazdur left FDA to avoid being part of “the...

The Cancer Letter ·

2025/12/10

Last week’s issue of The Cancer Letter featured great news and terrible news. On the one hand, Anthony G. Letai, the new director of the National Cancer Institute who has been regarded as a great choice for the position by oncology leaders, has stepped into the public sphere and has been spreading a message of stability and continuity. On the other hand, Richard Pazdur retired from his position as director of FDA’s Center for Drugs Evaluation and Research after a nearly three-decade career shaping

en

00:17:47

Roy Herbst remembers the late Edward Chu, “the...

The Cancer Letter ·

2025/12/03

Edward Chu, director of the Montefiore Einstein Comprehensive Cancer Center, died on Nov. 13 from glioblastoma. He was 66.In the most recent issue of The Cancer Letter, Roy S. Herbst, deputy director at Yale Cancer Center, penned an obituary for Chu chronicling the career and impact of the “baritone of reason.” In this week’s episode of The Cancer Letter Podcast, Herbst sat down with Paul Goldberg, editor of The Cancer Letter, and shared stories about meeting Chu on a sailboat in Rhode Island,

en

00:19:09

Oncofertility has been an overlooked standard of...

The Cancer Letter ·

2025/11/26

Recently, a wave of new private insurance mandates have swept the nation making fertility preservation a covered benefit for people with cancer in 21 states plus Washington, DC. Mia Sandino, an osteosarcoma survivor, chose not to undergo fertility preservation when she was diagnosed at 19. She didn’t know if she wanted kids, had no guarantee that her insurance would cover the extraordinary costs, and feared postponing treatment would delay her return to "normal life."This episode is

en

00:29:03

Ellen Sigal and Karen Knudsen “gush” about new CDER...

The Cancer Letter ·

2025/11/19

Last week, Richard Pazdur was named to the position of director of FDA’s Center for Drug Evaluation and Research. Much has been written about how Pazdur, with nearly a three-decade long career at the agency, represents a stabilizing choice for FDA as it faces inner and outer turmoil.Indeed, on this week’s episode of In the Headlines, we bring you the full audio of a conversation originally published in print in last week’s issue of The Cancer Letter between Ellen Sigal, chair and founder of Friends

en

00:33:24

Tidmarsh is out, Pazdur is in: FDA’s CDER under new...

The Cancer Letter ·

2025/11/12

Richard Pazdur, founding director of FDA’s Oncology Center of Excellence and long-time FDA visionary, has accepted the top job at FDA’s Center for Drug Evaluation and Research following George F. Tidmarsh’s dramatic ouster from the position. “This is big. Because, you know, the whole field of oncology over the past 25 years—and [Pazdur has] run the oncology division and decided which drugs would get on the market, which drugs won't get on the market. Everybody is speaking ‘Pazdurese,’” said

en

00:58:57

The Directors: Ruben Mesa and Kunle Odunsi on how...

The Cancer Letter ·

2025/11/07

At a time when federal immigration policies are becoming stricter, Kunle Odunsi, director of University of Chicago Medicine Comprehensive Cancer Center, reflected on the fact that cancer research is a highly international community.“I was born in Nigeria, I grew up in Nigeria, I went to medical school in Nigeria, and then I did some of my training in England, in the United Kingdom,” Odunsi said. “My residency in obstetrics and gynecology was at Yale School of Medicine, so it was a very welcoming

en

00:19:38

Site visits are gone, but outlook for new,...

The Cancer Letter ·

2025/11/05

One of the first things that happened as part of President Donald Trump’s “flooding of the zone” in January was the disappearance of the site visit as part of the Cancer Center Support Grant review.In last week’s cover story, Paul Goldberg, editor and publisher of The Cancer Letter, wrote about “the high level of consternation over the disappearance of the site visit from the CCSG review” and how cancer centers are adapting to the new, centralized review process. In this episode of The Cancer Letter

en

00:26:41

Early endpoints are a balance of risk and benefit

The Cancer Letter ·

2025/10/29

Early endpoints have the potential to get effective drugs to patients faster, but granting approval to drugs—even accelerated approval—comes with the risk that ineffective or even harmful drugs will be given to patients. “If we don't have these intermediate endpoints to get new drugs to patients, we'd have to wait… I think somebody mentioned in one of the conversations I had while I was reporting on this, that the readout would be upwards of 17 years to get information about these new drugs

en

00:35:00

Cliff Hudis on how AI in cancer care is...

The Cancer Letter ·

2025/10/22

“Our goal was very clear from the beginning, which was to develop a user-friendly simple chat-like interface that would provide specific high-quality answers to questions that our members would bring, utilizing only our content,” said Clifford A. Hudis, CEO of the American Society of Clinical Oncology and executive vice chair of the Conquer Cancer Foundation.On this week’s episode of The Cancer Letter Podcast, Hudis spoke with Paul Goldberg, publisher of The Cancer Letter, and Jacquelyn Cobb,

en

00:28:19

Latinx oncology leaders talk about the impact of...

The Cancer Letter ·

2025/10/15

In honor of Hispanic Heritage Month, this week’s episode of The Cancer Letter Podcast features three oncology leaders whose research focuses on identifying and solving health disparities specifically in the Latinx community. Ruben A. Mesa, Amelie Ramirez, and Luis Carvajal Carmona spoke about the concrete impact of federal policy stances on cancer outcomes in Latinx patients.Mesa, who is president of the Advocate Health Cancer National Service Line, president of the Atrium Health Levine Cancer, and

en

01:05:54

The Directors: Steven Artandi and Eric Winer on how...

The Cancer Letter ·

2025/10/10

With major leadership changes, grant disruptions and terminations, and a stoked distrust in science, Steven Artandi, the director of Stanford Cancer Center, worries that young investigators will feel disenchanted by the U.S. research atmosphere and take their work and study elsewhere. “The uncertainty in the current system is giving some people pause, especially younger people, whether they’re Americans or whether they trained abroad, as to whether the United States is the right place to spend their

en

00:27:11

Pulitzer-winning healthcare reporter Laurie McGinley...

The Cancer Letter ·

2025/10/08

“Patient stories, as you know, can either make or break a story,” said Laurie McGinley, a former health and science editor at The Washington Post who is now on the board of Patient Action for Cancer Research, or PACR, a new advocacy organization aimed at organizing and amplifying patient voices in an effort to protect life-saving federal health research.In last week’s issue, The Cancer Letter reporter Sara Willa Ernst wrote about how PACR is building a repository of patient stories to better connect

en

00:22:37

With Anthony Letai’s appointment, NCI is now under...

The Cancer Letter ·

2025/10/01

With little fan fare, Anthony Letai, a highly respected physician-scientist, was sworn in as the 18th director of the National Cancer Institute on Sept. 29. Then, two days later, on Oct. 1, the government shut down.The news of Letai’s apparent appointment was broken last week in the media, with no word from the White House. Although HHS has published a press release announcing Letai’s appointment, the White House is still silent on the matter. Meanwhile, Trump’s FDA initiated an unusual regulatory

en

00:19:15

Congress seems to have NCI’s back—is cautious...

The Cancer Letter ·

2025/09/24

With the fiscal year drawing to a close, grant funding from NCI is picking up speed, offering a glimmer of hope to cancer researchers who are beginning to feel cautiously optimistic about the road ahead.Following firm bipartisan pushback against the White House’s proposed budget cuts for FY2026, both the House and Senate have reaffirmed their support for biomedical research. At last week’s annual symposium marking the 50th anniversary of UNC Lineberger Comprehensive Cancer Center first securing its

en

62 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

The Dry Eye Treatment PODCAST

Dry Eye Treatment

Différent et alors ?

PATRICK SULAY

Kyle Kingsbury Podcast

Kyle Kingsbury

The Real Weight Loss Coach

Matty Lansdown